Table 1.
MIC (μg/mL) and MBC/MFC (μg/mL) of CHX and MNP@CHX against different pathogens including different clinical isolated from oral cavity/throat*
| Strain | Pathogen source | CHX
|
MNP@CHX
|
|---|---|---|---|
| MIC/MBC or MFC/MBIC | MIC/MBC or MFC/MBIC | ||
| Staphylococcus aureus (MRSA) | Laboratory strain | 16/16/32 | 4/8/16 |
| Staphylococcus aureus (MSSA) | Laboratory strain | 16/16/32 | 4/4/16 |
| Enterococcus faecalis | Surgery wound | 16/32/>32 | 8/16/32 |
| Escherichia coli | Surgery wound | 8/16/>32 | 0.25/1/2 |
| Pseudomonas aeruginosa | Laboratory strain | 32/>32/>32 | 16/32/>32 |
| Candida albicans | Laboratory strain | 16/32/>32 | 2/4/8 |
| Candida albicans* | Oral swabs | 16/32/>32 | 8/8/8 |
| Candida albicans* | Oral swabs | 16/16/16 | 2/2/2 |
| Candida albicans* | Throat swabs | 4/8/8 | 4/4/4 |
| Candida glabrata* | Throat swabs | 8/16/32 | 4/4/8 |
| Candida tropicalis* | Oral swabs | 4/8/8 | 4/4/4 |
Note:
*
Indicates clinical isolates from oral cavity/throat.
Abbreviations: CHX, chlorhexidine; MBC, minimal bactericidal concentration; MBIC, minimal biofilm inhibitory concentration; MFC, minimal fungicidal concentration; MIC, minimal inhibitory concentration; MNP@CHX, magnetic nanoparticles functionalized by chlorhexidine; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus.